Letters to the Editor nonspecific factors were more important than the specific treatment factors because there were no differences at each level. However, nonspecific factors are present in both explanatory and pragmatic trials, and there is no evidence that they were more important than usual in STAR*D. Therefore, while we felt it necessary to acknowledge in our review that STAR*D could not answer the sorts of questions that explanatory trials can answer, we are not of the opinion that this means the study's value as a pragmatic trial is in any way diminished.
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Dr Gorman and Dr Abi-Jaoude suggest that it is difficult to interpret the 67% cumulative remission rate in STAR*D because of the length of the trial. However, one of the hallmarks of a well-designed pragmatic study is a longer trial length, 1 making STAR*D's length a strength. More importantly, the study quoted by Dr Gorman and Dr Abi-Jaoude followed a group of patients whose untreated depression had a median time to remission of 13 weeks. By comparison, patients in STAR*D entered the trial with a median current episode length of 7.8 months 2 indicating a higher degree of illness chronicity that would, in general, be unlikely to remit spontaneously on a short time scale.
Pragmatic trials are valuable tools for determining the real-world impact of the treatments we offer. As such, they are often sought after by health system funders and government agencies. Explanatory trials also have their value; nonetheless, both of these types of trials must be judged on their quality rather than on the presence or absence of a placebo arm. Placebo-controlled trials help answer certain questions but are not the sole way to obtain valuable and meaningful data on treatment comparisons. We run a treatment service specialized in OCD as a primary diagnosis in which selective serotonin reuptake inhibitors (SSRIs) and group CBT are offered as first-line treatments. Our inclusion criteria are much broader than the ones from clinical trials with regulatory purposes but our treatment protocol is a structured one with sequential evaluations performed by blinded raters. Our sample has a comorbidity profile of up to 81% of patients having an additional psychiatric comorbidity. In a recent analysis of this sample, we found that response rates are much lower than previously reported and that major depression (among other psychiatric disorders) was associated with poor treatment response.
These findings suggest that OCD is much harder to treat than previous trials have estimated. Additional interventions may be needed in combination with SSRIs and CBT for patients with several psychiatric diagnoses. Future studies investigating longer treatment protocols, sequential treatment strategies, and contingencies analysis (functional analysis) are possible alternatives to improve the outcome of more complex samples.
